Is in a blatant upward trend, gel

€Striker

$SYK (+0,05 %)

$SYK (+0,05 %)

Stryker wants to buy Inari Medical for 4.9 billion dollars

The US medical technology provider Stryker wants to take over Inari Medical, another US-based company specializing in the treatment of vascular diseases. Is it currently worth buying Stryker shares?

The boards of Stryker and Inari have already agreed to the takeover, and Stryker will now make a cash offer of 80 dollars per Inari share. Inari's share price stood at 65 dollars at the close of trading on the US Nasdaq stock exchange yesterday evening. In total, Stryker expects the purchase to cost around 4.9 billion dollars.

Inari manufactures devices for the treatment of venous thromboembolism (VTE), a condition in which blood clots in the legs and in some cases can travel to the lungs. In the USA alone, up to 900,000 people are affected by VTE. The acquisition expands Stryker's offering in the treatment of peripheral vascular disease. The Group expects the acquisition to be completed in the first quarter of this year.

Hello everyone,

I have been saving for almost three years now with the $XDWD (+0,16 %) and have a portfolio of just under 17k.

In the coming year, I would like to invest a large sum x in individual shares with a view to the long term.

The shares will be held until I retire and will not be used to speculate on short-term gains.

I have selected the following shares:

$TSLA (+1,19 %)

$NVDA (+3,93 %)

$MSFT (+1,49 %)

$SYK (+0,05 %)

$LLY (+0,13 %)

$AAPL (-0,2 %)

$RHM (+0,5 %)

$AMZN (+0,37 %)

The shares are not spectacular, but are market leaders and big names in their sector. However, this is of course no guarantee of a promising future.

What do you think of these shares, even if they may seem boring?

Let's see - see potential - if it goes down further we will buy more

(Delayed) portfolio review October 2024 - A month with 5 share sales and one ETF sale

Even though October was just over two weeks ago, it feels like a different time. Germany still had an (unspeakable) traffic light government, in America the race for the White House was still open and a phone call between Scholz and Putin was unthinkable.

And even though November has been much more exciting on the stock market than October so far, October was a month of major changes from a personal perspective.

Apart from stock market investments, we are slowly starting to think about building a house. As a result, for the first time in a long time I made several sales in my portfolio and therefore also cleared out a little.

Previously this year, there were only 2 sales in my portfolio: at NVIDIA I took my stake out in February and since then have only let the profits run. In addition, in March I had Encavis after the takeover bid.

There were a total of 6 sales in October. For just under €7,000 I sold my China ETF which has recovered well over the last few months.

On the equity side, I have now sold most of the Corona Hype stocks and Match, Atlassian, Shopify and Block have been sold. In addition, I have also Pfizer sold. That was another €8,000, leaving only Sea from the Corona hype times, where I will remain invested for the time being, as it covers a completely different region geographically with Southeast Asia.

My savings quota will therefore be significantly reduced for the time being due to the upcoming house building project. From just under €1,500 to €2,000, it will only be €500-600 per month for the time being

Monthly view:

In total, October was +1,7%. This corresponds to price gains of ~5.000€.

The MSCI World (benchmark) was +0.9% and the S&P500 +1.5%

Winners & losers:

A look at the winners and losers is part of the usual picture:

On the winning side is, as so often NVIDIA is at the top with almost €3,000 in share price gains. It is followed by TSMC, Bitcoin, Alphabet and Palo Alto Networks with gains of €900-1,000 each.

On the loser side above all ASML made its contribution with price losses of almost €1,400. This was followed by Bechtle, Thermo Fisher, LVMH and Nike a broader mix of stocks that have not necessarily performed well recently. Nevertheless, all 5 loser stocks are still part of my savings plans.

The performance-neutral movements in October were just under €4,600. The sales proceeds are all still in cash accounts at the moment, so they have not yet flowed out of the assets. There will be a larger dip here at some point in the future.

Current year:

My performance in the current year is +27,5% and thus above my benchmark, the MSCI World with 23.7%.

In total, my portfolio currently stands at ~331.000€. This corresponds to an absolute growth of ~€79,000 in the current year 2023. ~53.000€ of this comes from price gains, ~3.000€ from dividends / interest and ~22.000€ from additional investments.

Dividend:

• Dividends in October were 32% above the previous year at ~€150
• TSMC is in the lead with a (gross) dividend of €30 every 3 months. TSMC has already raised the dividend for next year by 30% again
• In the current year, the dividends after 10 months are +25% over the first 9 months of 2023 at ~2.350€

Buys & sells:

• I bought in October for approx. 1.500€
• As always, my savings plans were executed:
• Blue chipsNovo Nordisk $NOVO B (+0,67 %) LVMH $MC (+0,29 %) Apple $AAPL (-0,2 %) Home Depot $HD (+0,29 %) Microsoft $MSFT (+1,49 %) Nike $NKE (+0,28 %) Starbucks $SBUX (+0,09 %) Stryker $SYK (+0,05 %) Texas Instruments $TXN (+1,3 %)
• 
  GrowthCrowdstrike $CRWD (+1,74 %) MercadoLibre $MELI (+0,65 %)
• 
  ETFsMSCI World $XDWD (+0,16 %) Nikkei 225 $XDJP (+0,6 %) and the WisdomTree Global Quality Dividend Growth $GGRP (+0,01 %)
• 
  Crypto: Bitcoin $BTC (-0,62 %) and Ethereum $ETH (-1,24 %)
• 
  Sales as mentioned, there were some in October with Match $MTCH (+0,81 %) Pfizer $PFE (+0,3 %) Block $SQ (+1,33 %) Shopify $SHOP (+1,63 %) Atlassian $TEAM Invesco MSCI China All-shares $MCHS (-1,16 %)

Target 2024:

My goal for this year is to reach €300,000 in my portfolio. Due to the extremely positive market development in the current year, my portfolio already stands at ~€331,000 at the end of October.

As of mid-November and thanks to the Trump rally, my portfolio is currently approaching €350,000 and was even slightly above this level a few days ago. However, with a larger cash portion that will sooner or later flow into financing as equity.

#dividends

#dividende

#rückblick

#depotupdate

#aktie

#stocks

#etfs

#crypto

#personalstrategy

In February 2024, I opened a securities account with Trade Republic and started saving 60 "stable" stocks from the S&5 500 per month with the aim of beating the S&P ETF in the long term. Since May, more than 30 additional stocks have been added and have proven to be an excellent decision so far. Among others $SFM (-0,25 %)
$AMP (+0,15 %)
$CMI (-0,45 %)
$SNA (+0,24 %)
$FI (+0,57 %)
$PANW (+0,07 %)
$ANET .

There are now over 150 positions and not only 🇺🇸 shares (over 90%) in the portfolio but also a handful from 🇩🇪🇬🇧🇳🇱🇯🇵🇸🇬. They still have to prove their quality, but so far only 🇺🇸 stocks have delivered performance.

9 months since the start, my "ETF" can keep up quite well although the goal of beating the S&P500 has not yet been achieved. But I'm close and in July the gap was somewhat wider.

Conclusion: The popular dividend stocks have not provided performance in the portfolio as $JNJ (+0,58 %)
$KO (+0,28 %)
$PG (+0,42 %)
$PEP (+0,35 %) The popular growth stocks from the semiconductor sector have not yet been able to prove their quality either. $ASML (+1,15 %)
$SNPS (+0,91 %)
$KLAC (-0,03 %)
$LRCX (+1,3 %)
$AMAT (+1,01 %) The healthcare sector has also been somewhat disappointing. $ISRG (+0,5 %) and $SYK (+0,05 %) are positive exceptions here.

The usual suspects, on the other hand, have performed very well, although Microsoft is lagging a little behind. Otherwise, the financial sector and almost all stocks in the industrial sector have performed well so far.

Let's see how things continue to develop.😁

All of these shares reached new ALL-TIME HIGHS at some point today ⤵️

Nvidia $NVDA (+3,93 %)

Amazon $AMZN (+0,37 %)

Netflix $NFLX (+1,04 %)

Walmart $WMT (+0,24 %)

JPMorgan $JPM (+0,04 %)

Goldman Sachs $GOS0

Palantir $PLTR (+3,36 %)

Blackrock $BLK

American Express $AXP (+0,32 %)

Arista $ANET

Apollo $APO PR A

Blackstone $BX (-0,22 %)

Booking $BKNG (+0,34 %)

Instacart $INSTA (+0 %)

Caterpillar $CAT (+0 %)

Capital One $COF (+1,37 %)

Discover Financial $DFS (+0,45 %)

Electronic Arts $EA (+1,03 %)

GE Vernova $GEV (+1,76 %)

Hilton $HLT (-0,63 %)

Howmet $HWM (+0,33 %)

Interactive Brokers $IBKR (+0,34 %)

$KKR (+0,01 %)

Cheniere $LNG (-0,58 %)

Morgan Stanley $MS (-0,05 %)

Marriot $MAR (+0,39 %)

Nasdaq $NDAQ (+0,12 %)

News Corp $NWSA (+1,13 %)

Oracle $ORCL (+8,22 %)

Palo Alto $PANW (+0,07 %)

ServiceNow $NOW (+0,89 %)

Steel Dynamics $STLD (+0,18 %)

Stryker $SYK (+0,05 %)

Royal Caribbean $RCL (+0,26 %)

Reddit $RDDT (-0,01 %)

Trade Desk $TTD (+0,66 %)

Visa $V (+0,02 %)

Wells Fargo $WFC (+0,12 %)

Aftermarket after quarterly figures

+17% Reddit $RDDT (-0,01 %)

+5% Snap $SNAP (-1,56 %)

+4% Alphabet $GOOGL (-0,98 %)
$GOOGL (-0,98 %)

+4% Stryker $SYK (+0,05 %)

+2% Visa $V (+0,02 %)

+1% Unum $UNM (-0,25 %)

+0% Chubb $8240

+0% Mondelez $MDLZ (-0,8 %)

-2% Chipotle Mexican Grill $CMG (+0,16 %)

-3% Caesars Entertainment $CZR (+0,27 %)

-3% First Solar $FSLR (+0,67 %)

-7% AMD $AMD (+0,95 %)

-15% Qorvo $QRVO (+2,25 %)

#aktien
#börse
#quartalszahlen
#earnings
#wallstreet

Stryker Q3 2024 $SYK (+0,05 %)

Financial performance:

Stryker reported impressive financial results for the third quarter of 2024. Net sales increased by 11,9 % to USD 5.5 billion. The company achieved organic sales growth of 11,5 %indicating strong demand in its product areas. The reported operating income margin was 19,7 %while the adjusted operating income margin increased by 130 basis points to 24,7 % increased. In addition, reported earnings per share (EPS) rose by 20,0 % to USD 2.16while adjusted EPS rose by 16,7 % to USD 2.87 increased.

Balance sheet analysis:

As of September 30, 2024, Stryker's total revenues amounted to USD 43.833 billionwhich represents an increase from USD 39.912 billion at the end of 2023. This growth was mainly driven by higher trade receivables and inventories. Both total debt and shareholders' equity increased, with non-current debt rising to USD 13.325 billion from USD 10.901 billion increased.

Income statement:

For the nine months ended September 30, 2024, Stryker reported net sales of USD 16.159 billionwhich represents an increase of 10,1 % compared to the previous year. Gross profit amounted to USD 10.266 billionwhich corresponds to a strong gross margin of 63,5 % corresponds to a strong gross margin. The operating result increased by 18,1 % to USD 3.108 billionwith a corresponding operating margin of 19,2 %.

Cash flow analysis:

Net cash provided by operating activities for the nine months amounted to USD 2.311 billionwhich represents a slight increase compared to USD 2.183 billion in the previous year. The company used USD 2.697 billion for investing activities, mainly for acquisitions and investments in property, plant and equipment. Financing activities generated a net amount of USD 1.269 billionprimarily through borrowings.

Key figures and profitability:

• Gross margin: 63.5% (for the nine months to September 30, 2024)
• Operating margin: 19.2% (for the same period)
• Net margin: Approximately 15.1% (for the nine months)

Segment analysis:

• MedSurg and Neurotechnology: Net sales increased in Q3 2024 by 12,8 % to USD 3.2 billionwith organic growth of 12,7 %.
• Orthopaedics and Spine: Net sales increased by 10,7 % to USD 2.3 billionwith organic growth of 9,7 %.

Competitive analysis:

Stryker continues to position itself strongly in the MedTech sector, driven by continuous product innovation and strategic acquisitions. The company operates in the upper market segment and is showing robust growth in its various business areas and geographical regions.

Forecasts and management commentary:

For the full year 2024, management is forecasting organic sales growth of between 9,5 % and 10,0 %with a positive price boost of 0,5 % to 1,0 %. Adjusted earnings per diluted share are expected to be in the range of USD 12.00 to USD 12.10 expected.

Risks and opportunities:

The main risks for Stryker include currency risks, regulatory changes and potential supply chain disruptions. Nevertheless, opportunities exist in ongoing product innovation, strategic acquisitions and expansion into international markets.

Summary and strategic implications:

Stryker's strong financial performance in Q3 2024, characterized by solid revenue growth and improved profitability, underscores the company's competitive position in the MedTech industry. The strategic focus on innovation and acquisitions is critical to the growth strategy. However, the company must skillfully manage potential risks related to regulatory changes and market volatility to maintain its positive momentum. Overall, Stryker appears financially stable with promising growth prospects.

Positive statements:

Strong sales growth: Stryker recorded a significant increase in net sales in the third quarter of 2024 of 11,9 % to USD 5.5 billionindicating robust demand for its products.

Improved profitability: The company achieved a reported operating income margin of 19,7 % and an adjusted operating income margin of 24,7 %indicating increased operational efficiency.

Increase in earnings per share: Reported earnings per share (EPS) increased by 20,0 % to USD 2.16which illustrates strong growth in net profit.

Segment performance: Both the MedSurg and Neurotechnology segments as well as Orthopaedics and Spine showed impressive sales growth with increases of 12,8 % and 10,7 %.

Positive cash flow from operating activities: For the nine months to September 30, 2024, the company generated USD 2.311 billion of net cash from operating activities for the nine months to September 30, 2024, indicating healthy cash generation.

Negative statements:

Increase in long-term debt: Stryker's long-term debt increased to USD 13.325 billion from USD 10.901 billionwhich could affect future financial flexibility.

High capital expenditures: The company used USD 2.697 billion on investing activities, mainly for acquisitions, which could put pressure on cash reserves if expected returns do not materialize.

Impact of foreign currencies: The company expects a slightly unfavorable impact on full-year net sales due to foreign currency exchange rates, which could impact profitability.

Regulatory and legal challenges: Stryker faces ongoing regulatory and legal matters that could result in additional costs and impact financial performance.

Potential supply chain disruptions: The company faces risks related to supply chain disruptions that could impact its ability to meet demand and sustain growth.